SEGA
MCID: SBP001
MIFTS: 47

Subependymal Giant Cell Astrocytoma (SEGA) malady

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Subependymal Giant Cell Astrocytoma

Aliases & Descriptions for Subependymal Giant Cell Astrocytoma:

Name: Subependymal Giant Cell Astrocytoma 12 50 56 14 69
Sega 12 50 56
Astrocytoma Subependymal Giant Cell 52

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:5077
MeSH 42 D001254
NCIt 47 C3696
SNOMED-CT 64 1586004 449799008
Orphanet 56 ORPHA251618
UMLS via Orphanet 70 C0205768
ICD10 via Orphanet 34 D43.2
UMLS 69 C0205768

Summaries for Subependymal Giant Cell Astrocytoma

MalaCards based summary : Subependymal Giant Cell Astrocytoma, also known as sega, is related to central neurocytoma and astrocytoma, and has symptoms including headache and seizures. An important gene associated with Subependymal Giant Cell Astrocytoma is TSC2 (Tuberous Sclerosis 2), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Angiopoietin Like Protein 8 Regulatory Pathway. The drugs Afinitor and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and endothelial, and related phenotypes are behavior/neurological and nervous system

Wikipedia : 71 Subependymal giant cell astrocytoma (SEGA, SGCA, or SGCT) is a low-grade astrocytic brain tumor... more...

Related Diseases for Subependymal Giant Cell Astrocytoma

Diseases related to Subependymal Giant Cell Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 129)
id Related Disease Score Top Affiliating Genes
1 central neurocytoma 30.1 GFAP SYP
2 astrocytoma 11.0
3 tuberous sclerosis 10.8
4 hemorrhagic proctocolitis 10.2 GFAP MTOR
5 melorheostosis with osteopoikilosis 10.2 TSC1 TSC2
6 hemolytic anemia due to adenylate kinase deficiency 10.2 MTOR TSC1
7 multiple mitochondrial dysfunctions syndrome 1 10.2 TSC1 TSC2
8 renal tubular transport disease 10.2 TSC1 TSC2
9 myelinoclastic diffuse sclerosis 10.2 GFAP S100B
10 bronchial mucus gland adenoma 10.2 GFAP S100B
11 spleen angiosarcoma 10.2 GFAP S100B
12 ovarian cystadenoma 10.2 GFAP S100B
13 trombiculiasis 10.2 GFAP S100B
14 biliary papillomatosis 10.2 GFAP S100B
15 porokeratosis 10.2 GFAP S100B
16 angiomyolipoma 10.2
17 sternum cancer 10.2 GFAP S100B
18 aids - neurological complications 10.2 TSC1 TSC2
19 vulvar squamous papilloma 10.2 GFAP S100B
20 buruli ulcer 10.2 TSC1 TSC2
21 diabetes hypogonadism deafness mental retardation 10.2 GFAP SYP
22 papillary tumor of the pineal region 10.2 GFAP SYP
23 brain stem ependymoma 10.2 GFAP SYP
24 intrahepatic bile duct adenoma 10.2 GFAP SYP
25 pilocytic astrocytoma of cerebellum 10.2 GFAP SYP
26 skin glomus tumor 10.2 GFAP S100B
27 children's interstitial lung disease 10.2 GFAP SYP
28 cervical benign neoplasm 10.2 GFAP SYP
29 myxopapillary ependymoma 10.2 GFAP SYP
30 epidermal appendage tumor 10.2 GFAP SYP
31 clear cell meningioma 10.2 GFAP SYP
32 cerebral folate receptor alpha deficiency 10.2 GFAP SYP
33 blood group incompatibility 10.2 GFAP SYP
34 mediastinal granular cell myoblastoma 10.2 GFAP SYP
35 mast-cell sarcoma 10.2 GFAP SYP
36 olfactory neuroblastoma 10.2 GFAP SYP
37 pineoblastoma 10.1 GFAP SYP
38 pneumothorax 10.1 GFAP SYP
39 brain stem astrocytic neoplasm 10.1 GFAP SYP
40 sebaceous adenoma 10.1 SYP TSC2
41 brain oligodendroglioma 10.1 GFAP SYP
42 arthus reaction 10.1 GFAP SYP
43 hunter macpherson syndrome 10.1 SYP TSC2
44 childhood central nervous system primitive neuroectodermal neoplasm 10.1 GFAP SYP
45 urea cycle disorder 10.1 GFAP S100B
46 factitious disorder 10.1 SYP TSC2
47 bone dysplasia azouz type 10.1 GFAP SYP
48 pancreatic cancer 10.1 GFAP SYP
49 pacinian tumor 10.1 GFAP SYP
50 temporal lobe neoplasm 10.1 GFAP SYP

Graphical network of the top 20 diseases related to Subependymal Giant Cell Astrocytoma:



Diseases related to Subependymal Giant Cell Astrocytoma

Symptoms & Phenotypes for Subependymal Giant Cell Astrocytoma

UMLS symptoms related to Subependymal Giant Cell Astrocytoma:


headache, seizures

MGI Mouse Phenotypes related to Subependymal Giant Cell Astrocytoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 FABP7 GFAP MTOR S100B SYP TSC1
2 nervous system MP:0003631 9.43 FABP7 GFAP MTOR SYP TSC1 TSC2
3 normal MP:0002873 9.02 MTOR S100B SYP TSC2 GFAP

Drugs & Therapeutics for Subependymal Giant Cell Astrocytoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Afinitor 17 46 EVEROLIMUS Novartis Approved March 2009

Drugs for Subependymal Giant Cell Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
2
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
3
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
4 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
6 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
9
Cisplatin Approved Phase 3,Phase 1 15663-27-1 84093 441203 2767
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
12
Ondansetron Approved Phase 3 99614-02-5 4595
13
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
14
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
15
Cyproheptadine Approved Phase 3 129-03-3 2913
16 Dermatologic Agents Phase 3,Phase 1
17 pancreatic polypeptide Phase 3
18 Analgesics Phase 3,Phase 1
19 Adjuvants, Anesthesia Phase 3
20 Narcotics Phase 3
21 Analgesics, Opioid Phase 3
22 Anesthetics Phase 3
23 Anesthetics, General Phase 3
24 Anesthetics, Intravenous Phase 3
25 Peripheral Nervous System Agents Phase 3,Phase 1
26 Liver Extracts Phase 3,Phase 1,Phase 2
27 Central Nervous System Depressants Phase 3
28 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
29 Gastrointestinal Agents Phase 3,Phase 1
30 Neurotransmitter Agents Phase 3
31 Dexamethasone 21-phosphate Phase 3,Phase 2,Phase 1
32 Emetics Phase 3
33 Antiemetics Phase 3,Phase 1
34 BB 1101 Phase 3,Phase 2,Phase 1
35 Autonomic Agents Phase 3,Phase 1
36
Histamine Phosphate Phase 3 51-74-1 65513
37
Serotonin Phase 3 50-67-9 5202
38 Serotonin Agents Phase 3
39 Serotonin Antagonists Phase 3
40 Histamine Antagonists Phase 3
41 Histamine H1 Antagonists Phase 3
42 Anti-Allergic Agents Phase 3
43 Antipruritics Phase 3
44 Cola Nutraceutical Phase 3
45
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
46
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
47
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
48
Topotecan Approved, Investigational Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
49
Tamoxifen Approved Phase 2 10540-29-1 2733526
50
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904

Interventional clinical trials:

(show top 50) (show all 57)
id Name Status NCT ID Phase
1 Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301 Active, not recruiting NCT02338609 Phase 4
2 Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Completed NCT00789828 Phase 3
3 Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Completed NCT00790400 Phase 3
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
5 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Active, not recruiting NCT01346267 Phase 3
6 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
7 Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer Unknown status NCT02188550 Phase 2
8 Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex Completed NCT00411619 Phase 1, Phase 2
9 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2
10 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2
11 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2
12 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2
13 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2
14 A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD Recruiting NCT02451696 Phase 2
15 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
16 Bevacizumab in Recurrent Grade II and III Glioma Active, not recruiting NCT01164189 Phase 2
17 Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Active, not recruiting NCT00553150 Phase 1, Phase 2
18 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting NCT00939770 Phase 1, Phase 2
19 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2
20 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1
21 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1
22 Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1
23 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1
24 AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors Completed NCT00326664 Phase 1
25 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1
26 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1
27 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1
28 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1
29 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1
30 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1
31 Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Completed NCT00498979 Phase 1
32 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1
33 Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00509431 Phase 1
34 PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors Completed NCT01158300 Phase 1
35 Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Completed NCT00138216 Phase 1
36 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1
37 Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors Completed NCT00503724 Phase 1
38 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1
39 Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas Recruiting NCT02186509 Phase 1
40 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1
41 Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors Terminated NCT00112619 Phase 1
42 Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors Terminated NCT00110032 Phase 1
43 Study of Blood Samples and Risk of Infection in Patients With Newly Diagnosed Malignant Supratentorial Astrocytoma Completed NCT00999622
44 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613
45 Study of Blood and Cheek Cell Samples From Patients With Glioma Completed NCT01009307
46 Study of Tissue Samples From Patients With Glioma or Other Brain Tumors Completed NCT00967200
47 Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma Completed NCT00401024
48 Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors Completed NCT00499798
49 Metabolic Syndrome in Childhood Cancer Survivors Completed NCT00920738
50 Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial Completed NCT00890435

Search NIH Clinical Center for Subependymal Giant Cell Astrocytoma

Genetic Tests for Subependymal Giant Cell Astrocytoma

Anatomical Context for Subependymal Giant Cell Astrocytoma

MalaCards organs/tissues related to Subependymal Giant Cell Astrocytoma:

39
Brain, Breast, Endothelial, Thyroid, Testes, Skin, Spinal Cord

Publications for Subependymal Giant Cell Astrocytoma

Articles related to Subependymal Giant Cell Astrocytoma:

(show top 50) (show all 144)
id Title Authors Year
1
Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation. ( 28074282 )
2017
2
Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study). ( 27860334 )
2016
3
Variability of Dose and Level of Sirolimus in a Patient With Tuberous Sclerosis Complex and Subependymal Giant Cell Astrocytoma. ( 27082208 )
2016
4
Subependymal giant cell astrocytoma in a genetically negative tuberous sclerosis complex adult: Case report. ( 27690251 )
2016
5
Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex. ( 26929034 )
2016
6
Intraoperative Squash Cytologic Features of Subependymal Giant Cell Astrocytoma. ( 27013816 )
2016
7
Subependymal giant cell astrocytoma: a lesion with activated mTOR pathway and constant expression of glutamine synthetase. ( 27390104 )
2016
8
Retraction Note to: Subependymal giant cell astrocytoma: current concepts, management, and future directions. ( 26922080 )
2016
9
Laser interstitial thermal therapy for subependymal giant cell astrocytoma: technical case report. ( 27690646 )
2016
10
Subependymal giant cell astrocytoma (SEGA): a case report and review of the literature. ( 26861567 )
2016
11
Thyroid transcription factor-1 distinguishes subependymal giant cell astrocytoma from its mimics and supports its cell origin from the progenitor cells in the medial ganglionic eminence. ( 27910945 )
2016
12
Role of mTOR signaling pathway in the pathogenesis of subependymal giant cell astrocytoma - A study of 28 cases. ( 27625244 )
2016
13
Imaging Manifestations of a Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis. ( 26942030 )
2016
14
EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. ( 27502586 )
2016
15
Natural History and Current Treatment Options for Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex. ( 26706014 )
2015
16
Erk activation as a possible mechanism of transformation of subependymal nodule into subependymal giant cell astrocytoma. ( 25909870 )
2015
17
Association between the growth rate of subependymal giant cell astrocytoma and age in patients with tuberous sclerosis complex. ( 26552385 )
2015
18
Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). ( 25929843 )
2015
19
BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas. ( 25346165 )
2015
20
Direct medical costs for patients with tuberous sclerosis complex and surgical resection of subependymal giant cell astrocytoma: a US national cohort study. ( 25525770 )
2015
21
Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. ( 26381530 )
2015
22
The clinical characteristics of subependymal giant cell astrocytoma: five cases. ( 25977907 )
2015
23
Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin. ( 26173783 )
2015
24
Subependymal giant cell astrocytoma in the absence of tuberous sclerosis complex: case report. ( 25978531 )
2015
25
Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. ( 25227171 )
2014
26
Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. ( 24507694 )
2014
27
The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. ( 24729041 )
2014
28
An unusually aggressive clinical behavior in a case of atypical subependymal giant cell astrocytoma. ( 25387628 )
2014
29
Everolimus Treatment for an Early Infantile Subependymal Giant Cell Astrocytoma With Tuberous Sclerosis Complex. ( 25143481 )
2014
30
Subependymal giant cell astrocytoma: current concepts, management, and future directions. ( 24549759 )
2014
31
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. ( 25456370 )
2014
32
Thyroid transcription factor-1 and epithelial membrane antigen expression in four cases of subependymal giant cell astrocytoma. ( 25195621 )
2014
33
A management strategy for intraventricular subependymal giant cell astrocytomas in tuberous sclerosis complex. ( 24180681 )
2014
34
Resection of subependymal giant cell astrocytoma guided by intraoperative magnetic resonance imaging and neuronavigation. ( 23397586 )
2013
35
Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. ( 24143074 )
2013
36
Congenital Segmental Lymphedema in Tuberous Sclerosis Complex With Associated Subependymal Giant Cell Astrocytomas Treated with Mammalian Target of Rapamycin Inhibitors. ( 24056156 )
2013
37
The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. ( 23183057 )
2013
38
Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations. ( 23391693 )
2013
39
Response of Subependymal Giant Cell Astrocytoma With Spinal Cord Metastasis to Everolimus. ( 24276039 )
2013
40
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. ( 23158522 )
2013
41
Subependymal Giant Cell Astrocytomas in Patients With Tuberous Sclerosis Complex:: Considerations for Surgical or Pharmacotherapeutic Intervention. ( 24105488 )
2013
42
Everolimus for the Treatment of Subependymal Giant Cell Astrocytoma Probably Causing Seizure Aggravation in a Child with Tuberous Sclerosis Complex: A Case Report. ( 24293099 )
2013
43
Subependymal giant cell astrocytoma with atypical clinical and pathological features: aA diagnostic pitfall. ( 23641712 )
2013
44
Subependymal giant cell astrocytoma associated with tuberous sclerosis presenting with intratumoral bleeding. Case report and review of literature. ( 23138436 )
2013
45
Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. ( 22805244 )
2013
46
Subependymal giant cell astrocytoma with intratumoral hemorrhage. ( 23414132 )
2013
47
Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. ( 23325902 )
2013
48
Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. ( 23567018 )
2013
49
Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. ( 24138953 )
2013
50
Advances in the management of subependymal giant cell astrocytoma. ( 22562196 )
2012

Variations for Subependymal Giant Cell Astrocytoma

Expression for Subependymal Giant Cell Astrocytoma

Search GEO for disease gene expression data for Subependymal Giant Cell Astrocytoma.

Pathways for Subependymal Giant Cell Astrocytoma

Pathways related to Subependymal Giant Cell Astrocytoma according to GeneCards Suite gene sharing:

(show all 29)
id Super pathways Score Top Affiliating Genes
1 12.35 MTOR TSC1 TSC2
2
Show member pathways
12.3 MTOR TSC1 TSC2
3
Show member pathways
12.27 MTOR TSC1 TSC2
4
Show member pathways
12.21 MTOR TSC1 TSC2
5
Show member pathways
12.19 MTOR TSC1 TSC2
6 12.18 FABP7 GFAP S100B SYP
7
Show member pathways
12.17 MTOR TSC1 TSC2
8
Show member pathways
12.16 MTOR TSC1 TSC2
9
Show member pathways
12.08 MTOR TSC1 TSC2
10 12.02 MTOR TSC1 TSC2
11
Show member pathways
11.97 MTOR TSC1 TSC2
12
Show member pathways
11.94 MTOR TSC1 TSC2
13 11.89 MTOR TSC1 TSC2
14
Show member pathways
11.87 MTOR TSC1 TSC2
15
Show member pathways
11.85 MTOR TSC1 TSC2
16 11.78 MTOR TSC1 TSC2
17 11.74 MTOR TSC1 TSC2
18 11.65 MTOR TSC1 TSC2
19 11.51 MTOR TSC1 TSC2
20 11.3 TSC1 TSC2
21 11.29 MTOR TSC2
22 11.28 MTOR TSC1 TSC2
23 11.16 MTOR TSC1 TSC2
24 11.07 MTOR TSC2
25 11.01 MTOR TSC2
26 10.96 MTOR TSC1 TSC2
27 10.92 FABP7 GFAP NES S100B SYP
28 10.79 MTOR TSC1
29 10.66 MTOR TSC1 TSC2

GO Terms for Subependymal Giant Cell Astrocytoma

Cellular components related to Subependymal Giant Cell Astrocytoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 lysosome GO:0005764 9.33 GFAP MTOR TSC2
2 intermediate filament cytoskeleton GO:0045111 8.96 GFAP NES
3 TSC1-TSC2 complex GO:0033596 8.62 TSC1 TSC2

Biological processes related to Subependymal Giant Cell Astrocytoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 regulation of protein kinase activity GO:0045859 9.48 MTOR TSC1
2 positive regulation of stress fiber assembly GO:0051496 9.46 MTOR TSC1
3 negative regulation of TOR signaling GO:0032007 9.43 TSC1 TSC2
4 cell cycle arrest GO:0007050 9.43 MTOR TSC1 TSC2
5 negative regulation of insulin receptor signaling pathway GO:0046627 9.4 TSC1 TSC2
6 positive regulation of macroautophagy GO:0016239 9.37 TSC1 TSC2
7 regulation of neuronal synaptic plasticity GO:0048168 9.32 S100B SYP
8 negative regulation of macroautophagy GO:0016242 9.16 MTOR TSC1
9 anoikis GO:0043276 8.96 MTOR TSC2
10 negative regulation of cell size GO:0045792 8.62 MTOR TSC1

Sources for Subependymal Giant Cell Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....